amoxicillin/vonoprazan
Jump to navigation
Jump to search
Indications
- treatment of Helicobacter pylori infection (FDA approved May 2022)
Adverse effects
- dysgeusia, diarrhea, abdominal pain, headache, nasopharyngitis, hypertension, vulvovaginal candidiasis
- Stevens-Johnson syndrome & toxic epidermal necrolysis
- C difficile-associated diarrhea
Notes
- available Fall 2022
More general terms
Components
References
- ↑ Hamza Z Two New Regimens Win FDA Approval for H. Pylori Infection. Dual and triple vonoprazan-based treatments offer physicians another set of options. MedPage Today May 4, 2022 https://www.medpagetoday.com/gastroenterology/generalgastroenterology/98547
- ↑ Rokkas T, Ekmektzoglou K, Niv Y, et al. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2024 Sep 19 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39298553 https://journals.lww.com/ajg/abstract/9900/comparative_efficacy_and_safety_of.1334.aspx